个人简历

翁锦生，男，研究员。毕业于南昌大学预防医学（本科），中山大学临床内科学（硕士）和德克萨斯农工(A&M)大学健康医学中心癌症和干细胞生物学（博士）。曾就职于美国癌症专业排名第一的安德森癌症中心，任助理教授。2011年获得杰出肿瘤免疫学家玛格丽特.克里普克奖，美国血液病学会(ASH)优秀摘要奖。已发表文章20余篇，总引用次数近500。担任美国癌症，免疫，血液病，肿瘤免疫治疗等多个科学协会会员及杂志审稿人。在利用组织特异性分子进行临床肿瘤早期诊断和免疫治疗方面有较高的造诣，研究获得美国NIH，基金会和中国国家自然科学基金委资助。

研究领域

肿瘤免疫治疗及早期诊断

近期论文

1. Weng, J., Baio FE, Moriarty KE, Torikai H, Wang H, Liu Z, Maiti S, Gwak D, Popescu MS, Cha SC, Cooper LJ, Neelapu SS, Kwak LW. IL-15 enhances the anti-tumor effect of human antigen-specific CD8 T cells by cellular senescence delay Oncommunology 2016 Oct 7; 5(12):e1237327. (IF:7.6, First and corresponding author )
2. Weng, J., Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW. Targeting B-cell malignancies through human B-cell receptor specific CD4 T cells OncoImmunology 2016 Sep 19;5(11):e1232220. (IF:7.6, First and corresponding author)
3. Weng, J., Rawal, S., Chu, F., Park, H.J., Sharma, R., Delgado, D.A., Fayad, L., Fanale, M., Romaguera, J., Luong, A., et al. 2012. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 120:1613-1623. （IF: 13.2）
4. Weng, J., Cha, S.C., Matsueda, S., Alatrash, G., Popescu, M.S., Yi, Q., Molldrem, J.J., Wang, M., Neelapu, S.S., and Kwak, L.W. 2011. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 17:5945-5952. (IF:9.2)
5. Weng, J., Luo, J., Cheng, X., Jin, C., Zhou, X., Qu, J., Tu, L., Ai, D., Li, D., Wang, J., et al. 2008. Deletion of G protein-coupled receptor 48 leads to ocular anterior segment dysgenesis (ASD) through down-regulation of Pitx2. Proc Natl Acad Sci U S A 105:6081-6086. (IF:9.7)